Capital Impact Advisors LLC Has $766,000 Stock Position in Exelixis, Inc. (NASDAQ:EXEL)

Capital Impact Advisors LLC lowered its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 20.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 34,104 shares of the biotechnology company’s stock after selling 8,805 shares during the period. Exelixis makes up 2.2% of Capital Impact Advisors LLC’s investment portfolio, making the stock its 15th biggest holding. Capital Impact Advisors LLC’s holdings in Exelixis were worth $766,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. Farallon Capital Management LLC raised its holdings in shares of Exelixis by 1.6% during the second quarter. Farallon Capital Management LLC now owns 27,102,500 shares of the biotechnology company’s stock valued at $608,993,000 after purchasing an additional 424,000 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Exelixis by 0.4% during the second quarter. Renaissance Technologies LLC now owns 15,163,066 shares of the biotechnology company’s stock valued at $340,714,000 after purchasing an additional 61,350 shares during the period. LSV Asset Management raised its holdings in shares of Exelixis by 107.7% during the second quarter. LSV Asset Management now owns 5,763,728 shares of the biotechnology company’s stock valued at $129,511,000 after purchasing an additional 2,989,021 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Exelixis by 7.3% during the second quarter. Dimensional Fund Advisors LP now owns 5,137,201 shares of the biotechnology company’s stock valued at $115,434,000 after purchasing an additional 349,837 shares during the period. Finally, AQR Capital Management LLC raised its holdings in shares of Exelixis by 12.7% during the second quarter. AQR Capital Management LLC now owns 3,281,578 shares of the biotechnology company’s stock valued at $73,425,000 after purchasing an additional 370,199 shares during the period. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Trading Down 1.1 %

Shares of EXEL stock opened at $25.96 on Monday. The stock has a market capitalization of $7.87 billion, a P/E ratio of 40.56, a PEG ratio of 0.56 and a beta of 0.54. The firm’s 50 day moving average is $25.56 and its 200 day moving average is $23.48. Exelixis, Inc. has a 12 month low of $18.64 and a 12 month high of $27.83.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Tuesday, August 6th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.44. Exelixis had a net margin of 17.38% and a return on equity of 15.54%. The business had revenue of $637.18 million for the quarter, compared to analysts’ expectations of $468.21 million. On average, equities analysts predict that Exelixis, Inc. will post 1.59 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Truist Financial reissued a “buy” rating and set a $33.00 target price (up from $32.00) on shares of Exelixis in a research report on Thursday, August 8th. StockNews.com raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 13th. UBS Group assumed coverage on shares of Exelixis in a research report on Thursday, September 19th. They issued a “neutral” rating and a $30.00 price objective for the company. Oppenheimer reaffirmed an “outperform” rating and issued a $29.00 price objective on shares of Exelixis in a research report on Tuesday, July 30th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $27.00 price objective on shares of Exelixis in a research report on Thursday. Five analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $27.67.

Insiders Place Their Bets

In other Exelixis news, EVP Jeffrey Hessekiel sold 25,000 shares of the stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $26.38, for a total value of $659,500.00. Following the sale, the executive vice president now directly owns 605,325 shares in the company, valued at approximately $15,968,473.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Exelixis news, EVP Jeffrey Hessekiel sold 25,000 shares of the stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $26.38, for a total value of $659,500.00. Following the sale, the executive vice president now directly owns 605,325 shares in the company, valued at approximately $15,968,473.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Dana Aftab sold 95,000 shares of the firm’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $25.00, for a total transaction of $2,375,000.00. Following the sale, the executive vice president now owns 520,990 shares in the company, valued at approximately $13,024,750. The disclosure for this sale can be found here. Insiders have sold 327,858 shares of company stock worth $8,640,129 in the last three months. 2.85% of the stock is currently owned by corporate insiders.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.